Bluebird Bio Inc (BLUE) 159.49 $BLUE Forget Bio
Post# of 273333
Posted On: 07/28/2015 12:17:31 AM
Bluebird Bio Inc (BLUE) 159.49 $BLUE
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), LGND: 102.55 (+0.46), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82), EXEL: 5.44 (-0.15), CELG: 132.56 (-2.34)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), NBIX: 49.34 (-2.16), ISIS: 53.68 (+0.53), SRPT: 32.00 (-0.63), RCPT: 227.09 (-0.91)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 159.49 (+0.58)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 159.49 (+0.58), CELG: 132.56 (-2.34)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 159.49 (+0.58)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 159.49 (+0.58), DRNA: 12.70 (-0.32), ALNY: 128.82 (-0.80), TKMR: 10.30 (unch), JUNO: 47.80 (-2.36), CELG: 132.56 (-2.34)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 159.49 (+0.58), HZNP: 36.13 (-1.07), AAL: 40.14 (+0.51), SDRL: 8.28 (-0.37), HNT: 65.60 (-0.07)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 17.41 (-0.39), BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), GILD: 110.54 (-2.29), AZN: 32.71 (-33.05), AMGN: 165.54 (+6.95), JUNO: 47.80 (-2.36), SRNE: 23.70 (+0.19), XLRN: 28.50 (-1.32), CELG: 132.56 (-2.34)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 159.49 (+0.58), KITE: 68.86 (+0.14), ADMS: 26.15 (-0.65), ACHN: 8.28 (-0.41)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 159.49 (+0.58), GILD: 110.54 (-2.29), MNKD: 4.77 (-0.21), PBYI: 84.69 (-4.60), KERX: 7.66 (-0.18), CELG: 132.56 (-2.34)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 159.49 (+0.58), KITE: 68.86 (+0.14), CLLS: 34.87 (-0.70), JUNO: 47.80 (-2.36), CYAD: 56.74 (-1.93), CELG: 132.56 (-2.34)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.19 (+0.28), NFLX: 106.43 (-2.91), BLUE: 159.49 (+0.58), AMZN: 531.41 (+1.99), TSLA: 253.01 (-12.40), KITE: 68.86 (+0.14), LBIO: 8.79 (-0.64), JUNO: 47.80 (-2.36), EGRX: 91.23 (-1.99)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.19 (+0.28), NFLX: 106.43 (-2.91), BLUE: 159.49 (+0.58), AMZN: 531.41 (+1.99), TSLA: 253.01 (-12.40), KITE: 68.86 (+0.14), LBIO: 8.79 (-0.64), JUNO: 47.80 (-2.36), EGRX: 91.23 (-1.99)
Biotech Investors Should Read Bibliographies Of Chief Scientific Officers
Intrepid Investor - at Seeking Alpha - Tue Jun 30, 11:42AM CDT
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), TBIO: 1.61 (-0.04), SGMO: 8.87 (-0.29), SRNE: 23.70 (+0.19), CELG: 132.56 (-2.34), VICL: 0.61 (-0.02), GILD: 110.54 (-2.29), SGEN: 48.06 (-0.37), AEZS: 0.19 (-0.02), REGN: 540.03 (-1.82)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), LGND: 102.55 (+0.46), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82), EXEL: 5.44 (-0.15), CELG: 132.56 (-2.34)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), NBIX: 49.34 (-2.16), ISIS: 53.68 (+0.53), SRPT: 32.00 (-0.63), RCPT: 227.09 (-0.91)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 159.49 (+0.58)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.19 (+0.28), BLUE: 159.49 (+0.58), AMBA: 119.45 (-4.78), NFLX: 106.43 (-2.91), EYES: 14.36 (-0.09), AMZN: 531.41 (+1.99), ZIOP: 12.03 (-0.45), LNKD: 220.66 (-4.40), FB: 94.17 (-2.78), RCPT: 227.09 (-0.91), LBIO: 8.79 (-0.64), INTC: 28.35 (+0.29), ONTY: 3.35 (-0.15), CELG: 132.56 (-2.34)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 159.49 (+0.58), NFLX: 106.43 (-2.91), AMZN: 531.41 (+1.99), TDOC: 31.31 (-0.84), GUID: 9.35 (-0.30), CBM: 45.70 (-3.21), FB: 94.17 (-2.78), LBIO: 8.79 (-0.64), GOOGL: 658.27 (+3.50), MBLY: 58.79 (-1.60), AAPL: 122.77 (-1.73)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 159.49 (+0.58), CELG: 132.56 (-2.34)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 159.49 (+0.58)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 159.49 (+0.58), DRNA: 12.70 (-0.32), ALNY: 128.82 (-0.80), TKMR: 10.30 (unch), JUNO: 47.80 (-2.36), CELG: 132.56 (-2.34)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 159.49 (+0.58), HZNP: 36.13 (-1.07), AAL: 40.14 (+0.51), SDRL: 8.28 (-0.37), HNT: 65.60 (-0.07)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 17.41 (-0.39), BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), GILD: 110.54 (-2.29), AZN: 32.71 (-33.05), AMGN: 165.54 (+6.95), JUNO: 47.80 (-2.36), SRNE: 23.70 (+0.19), XLRN: 28.50 (-1.32), CELG: 132.56 (-2.34)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 159.49 (+0.58), KITE: 68.86 (+0.14), ADMS: 26.15 (-0.65), ACHN: 8.28 (-0.41)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 159.49 (+0.58), GILD: 110.54 (-2.29), MNKD: 4.77 (-0.21), PBYI: 84.69 (-4.60), KERX: 7.66 (-0.18), CELG: 132.56 (-2.34)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 159.49 (+0.58), KITE: 68.86 (+0.14), CLLS: 34.87 (-0.70), JUNO: 47.80 (-2.36), CYAD: 56.74 (-1.93), CELG: 132.56 (-2.34)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.19 (+0.28), NFLX: 106.43 (-2.91), BLUE: 159.49 (+0.58), AMZN: 531.41 (+1.99), TSLA: 253.01 (-12.40), KITE: 68.86 (+0.14), LBIO: 8.79 (-0.64), JUNO: 47.80 (-2.36), EGRX: 91.23 (-1.99)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.19 (+0.28), NFLX: 106.43 (-2.91), BLUE: 159.49 (+0.58), AMZN: 531.41 (+1.99), TSLA: 253.01 (-12.40), KITE: 68.86 (+0.14), LBIO: 8.79 (-0.64), JUNO: 47.80 (-2.36), EGRX: 91.23 (-1.99)
Biotech Investors Should Read Bibliographies Of Chief Scientific Officers
Intrepid Investor - at Seeking Alpha - Tue Jun 30, 11:42AM CDT
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), TBIO: 1.61 (-0.04), SGMO: 8.87 (-0.29), SRNE: 23.70 (+0.19), CELG: 132.56 (-2.34), VICL: 0.61 (-0.02), GILD: 110.54 (-2.29), SGEN: 48.06 (-0.37), AEZS: 0.19 (-0.02), REGN: 540.03 (-1.82)
(0)
(0)